Therapy for Addiction

 

101021
   
Technology Overview

UC researchers have developed a monoclonal antibody that recognizes and effectively binds cocaine. By administering this antibody, cocaine concentrations are much lower in the brain, which aid individuals battling drug addiction to stay in recovery. Preclinical testing and characterization of the antibody has been performed. This novel immunotherapy for cocaine abuse will soon enter human clinical trials.

Background

Cocaine is a powerfully addictive stimulant that directly affects the brain. Cocaine use ranges from occasional use to repeated or compulsive use, with a variety of patterns between these extremes. There is no safe way to use cocaine and any route of administration can lead to absorption of toxic amounts of cocaine, leading to acute cardiovascular or cerebrovascular emergencies that could result in sudden death. Repeated cocaine use by any route of administration can produce dependence, addiction and other adverse health consequences. Despite decades of basic and clinical research there are currently no medications approved to treat cocaine dependence, addiction, overdose or to help prevent relapse.

Advantages and Benefits
  • Novel Immunotherapy for Cocaine Use Disorder
  • Infrequent Dosing and Long-lasting Protection
  • Advanced Stage of Preclinical Development
  •  
  •  
  •  
Patents
Title Country Serial No. Patent No. File Date Issued Date
Compositions and Methods for Treating Cocaine-Related Disorders United States 11/788,808 9,758,593 4/20/2007 9/12/2017
Compositions and Methods for Treating Cocaine-Related Disorders United States 14/208,597 9,957,332 3/13/2014 5/1/2018
Compositions and Methods for Treating Cocaine-Related Disorders United States 15/677,401 10,501,556 8/15/2017 12/10/2019
Other Media
Inventor(s)
Contact
Jill Uhl
Sr. Licensing Associate, Life Sciences
Lead Inventor
Keywords